Randomised Controlled Trial (RCT)

Randomised Controlled Trial (RCT) is the gold-standard study design for evaluating therapeutic interventions, employing random assignment to allocate participants between treatment groups and thereby minimising bias that could confound results. This rigorous methodology provides the highest-quality evidence for establishing causality between interventions and outcomes, forming the evidentiary foundation for regulatory approvals and clinical practice guidelines worldwide.

Randomisation ensures treatment groups are statistically comparable at baseline, distributing both known and unknown confounding factors evenly across arms. RCTs typically incorporate additional design elements including blinding where participants and investigators remain unaware of treatment assignments, placebo controls, and intention-to-treat analyses that preserve randomisation benefits. The biopharmaceutical industry conducts thousands of RCTs annually, investing billions in these definitive studies that support marketing applications. Regulatory authorities require well-designed RCTs demonstrating favourable benefit-risk profiles before approving new therapeutics. Adaptive RCT designs have emerged to improve efficiency, allowing protocol modifications based on accumulating data whilst maintaining statistical validity. Pragmatic RCTs conducted in real-world settings complement traditional explanatory trials. Challenges persist including recruitment difficulties, high costs, and ethical considerations when withholding effective treatments from control groups. Industry leaders continuously refine RCT methodologies, incorporating patient-centricity principles, decentralised trial elements, and innovative endpoints that accelerate development timelines.